Evidence map›Paper›PMID 40719359›Full record

ArticleAdvanced healthcare materials2025

Inhalability and Bioactivity of Spray-Dried versus Pressurized Gas eXpanded Liquid Technology-Processed Yeast Beta-Glucan Microparticles for Anti-Fibrotic Therapies.

Nate Dowdall, Safaa Naiel, Quan Zhou, Pareesa Ali, Tamana Rubina Yousof, Emily Wong, Ricardo Couto, Byron Yépez, Bernhard Seifried, Paul Moquin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nate DowdallDepartment of Chemical Engineering, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.ORCID 0009-0008-2367-8742
Safaa NaielDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.
Quan ZhouDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.
Pareesa AliDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.
Tamana Rubina YousofDepartment of Medicine, Division of Nephrology, St. Joseph's Healthcare Hamilton, Hamilton Center for Kidney Research, McMaster University, Hamilton, ON, L8N 4A6, Canada.ORCID 0000-0002-9527-7939
Emily WongCeapro, Inc., 7824-51 Avenue NW, Edmonton, Alberta, T6E 6W2, Canada.
Ricardo CoutoCeapro, Inc., 7824-51 Avenue NW, Edmonton, Alberta, T6E 6W2, Canada.
Byron YépezCeapro, Inc., 7824-51 Avenue NW, Edmonton, Alberta, T6E 6W2, Canada.
Bernhard SeifriedCeapro, Inc., 7824-51 Avenue NW, Edmonton, Alberta, T6E 6W2, Canada.ORCID 0000-0003-3867-1021
Paul MoquinCeapro, Inc., 7824-51 Avenue NW, Edmonton, Alberta, T6E 6W2, Canada.ORCID 0000-0003-2094-7923
Rod RhemFirestone Research Aerosol Laboratory, St. Joseph's Healthcare and Faculty of Health Sciences, Department of Medicine, McMaster University, Hamilton, Ontario, L8N 4A6, Canada.
Myrna DolovichFirestone Research Aerosol Laboratory, St. Joseph's Healthcare and Faculty of Health Sciences, Department of Medicine, McMaster University, Hamilton, Ontario, L8N 4A6, Canada.ORCID 0000-0002-3142-0281
Martin Rainer KolbDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.ORCID 0000-0003-3837-1467
Kjetil AskDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.ORCID 0000-0002-0202-735X
Todd HoareDepartment of Chemical Engineering, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.ORCID 0000-0002-5698-8463

Funding

CIHR 476552Mitacs Canada IT18595Mitacs Canada IT29330Mitacs Canada KAMitacs Canada THThe Natural Sciences and Engineering Research Council of Canada CHRPJ-538813-2019
6 · The paper itself

Abstract

Current anti-fibrotic therapeutics for idiopathic pulmonary fibrosis (IPF) slow disease progression but are non-curative and have systemic side effects, promoting interest in therapies that can repolarize macrophages away from their pro-fibrotic phenotype. While yeast beta-glucan (YBG) offers therapeutic potential in reprogramming macrophages toward an anti-fibrotic phenotype, YBG processing must be optimized to promote inhalability while preserving its biological activity. Herein, the biological and inhalation performance of YBG processed via Pressurized Gas eXpanded liquids technology (PGX

Indexed as

Antifibrotic Agentsbeta-GlucansIdiopathic Pulmonary FibrosisMacrophagesSaccharomyces cerevisiaeAdministration, InhalationAnimalsFemaleHumansInflammation MediatorsLungMiceMice, Inbred C57BLParticle SizePhagocytosisPressureAntifibrotic Agentsbeta-GlucansInflammation Mediatorsfibrosisimmunomodulationinhalationmacrophagesyeast beta‐glucan

Identifiers

PMID40719359
PMCPMC12616587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.